First-in-man single ascending dose study with an oral solution of EV-077.
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2012
At a glance
- Drugs SER 150 (Primary)
- Indications Arterial thrombosis; Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Evolva SA
- 20 Jul 2012 Results published in the European Journal of Clinical Pharmacology.
- 16 Dec 2010 Status changed from recruiting to completed, as reported in and Evolva media release.
- 16 Jul 2009 Single ascending dose portion of the trial completed, as reported by Evolva Biotech. The multiple ascending dose phase will be conducted next.